Literature DB >> 16984810

RNAi therapy for neurodegenerative diseases.

Ryan L Boudreau1, Beverly L Davidson.   

Abstract

RNA interference (RNAi) mediates gene silencing in a sequence-specific manner and has proven to be an exceptionally valuable discovery for bench scientists. In the laboratory, RNAi technologies provide efficient means for validating drug targets and for performing reverse genetics to study gene function (Friedman and Perrimon, 2004). Patients may also benefit from RNAi as applications extend to potential human therapies. RNAi-based treatments are being investigated and may provide hope for patients suffering from cancer, viral infections, or genetic diseases for which effective therapies are currently lacking. Notably, several independent studies have demonstrated that RNAi therapy can improve disease phenotypes in various mouse models of human disease. In this chapter, we focus on the potential of RNAi in treating neurologic diseases for which reduction of mutant or toxic gene expression may provide therapeutic benefit. We discuss approaches to achieving RNAi in vivo, progress in the field, and the potential pitfalls associated with RNAi-based therapies.

Entities:  

Mesh:

Year:  2006        PMID: 16984810     DOI: 10.1016/S0070-2153(06)75003-7

Source DB:  PubMed          Journal:  Curr Top Dev Biol        ISSN: 0070-2153            Impact factor:   4.897


  6 in total

1.  Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.

Authors:  Edgardo Rodríguez-Lebrón; Cynthia M Gouvion; Steven A Moore; Beverly L Davidson; Henry L Paulson
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

2.  Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.

Authors:  Hongyan Wang; Animesh Ghosh; Huricha Baigude; Chao-Shun Yang; Linghua Qiu; Xugang Xia; Hongxia Zhou; Tariq M Rana; Zuoshang Xu
Journal:  J Biol Chem       Date:  2008-03-26       Impact factor: 5.157

Review 3.  Lentiviral delivery of short hairpin RNAs.

Authors:  N Manjunath; Haoquan Wu; Sandesh Subramanya; Premlata Shankar
Journal:  Adv Drug Deliv Rev       Date:  2009-03-31       Impact factor: 15.470

4.  Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.

Authors:  Laura de Yñigo-Mojado; Itziar Martín-Ruíz; James D Sutherland
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

Review 5.  Ribonucleic acid interference induced gene knockdown.

Authors:  Sruthima N V S Gottumukkala; C D Dwarakanath; Sabitha Sudarsan
Journal:  J Indian Soc Periodontol       Date:  2013-07

6.  Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells.

Authors:  Ye Wang; Tao Jin; Xueming Dai; Dongwang Yan; Zhihai Peng
Journal:  Mol Med Rep       Date:  2016-09-05       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.